Upgrade

Finvezto Toolkit

Natco Pharma received a USFDA inspection report classing its Visakhapatnam formulations plant as voluntary action indicated.

Legal · 20 Nov 2026 · Natco Pharma (NATCOPHARM)

The 17-21 August inspection had ended with four Form 483 observations. VAI closes it without regulatory action.

Company page

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.